Literature DB >> 15900581

Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.

Eiichi Ishikawa1, Shinichiro Motohashi, Aki Ishikawa, Toshihiro Ito, Tetsuro Uchida, Takaaki Kaneko, Yuriko Tanaka, Shigetoshi Horiguchi, Yoshitaka Okamoto, Takehiko Fujisawa, Koji Tsuboi, Masaru Taniguchi, Akira Matsumura, Toshinori Nakayama.   

Abstract

Human invariant Valpha24+ natural killer T (NKT) cells display potent antitumor activity upon stimulation. Activation of endogenous Valpha24+ NKT cells would be one strategy for the treatment of cancer patients. For example, dendritic cells (DCs) loaded with a glycolipid NKT cell ligand, alpha-galactosylceramide (alphaGalCer, KRN7000), are a possible tool for the activation and expansion of functional Valpha24+ NKT cells in vivo. In this report, we demonstrate that the levels of expansion and the ability to produce IFN-gamma of Valpha24+ NKT cells induced by alphaGalCer-loaded whole PBMCs cultured with IL-2 and GM-CSF (IL-2/GM-CSF-cultured PBMCs) were superior to those of cells induced by monocyte-derived CD11c+ DCs (moDCs) developed with IL-4 and GM-CSF. Interestingly, CD11c+ cells in the IL-2/GM-CSF-cultured PBMCs showed a mature phenotype without further stimulation and exerted potent stimulatory activity on Valpha24+ NKT cells to enable them to produce IFN-gamma preferentially at an extent equivalent to mature moDCs induced by stimulation with LPS or a cytokine cocktail. Cocultivation with CD11c- cells in the IL-2/GM-CSF-cultured PBMCs induced maturation of moDCs. In particular, CD11c-CD3+ T cells appeared to play important roles in DC maturation. In addition, TNF-alpha was preferentially produced by CD11c-CD3+ T cells in IL-2/GM-CSF-cultured PBMCs and was involved in the maturation of moDCs. Thus, the maturation of DCs induced by CD11c- T cells through TNF-alpha production appears to result in the efficient expansion and activation of Valpha24+ NKT cells to produce IFN-gamma preferentially.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15900581     DOI: 10.1002/ijc.21197

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.

Authors:  Kaoru Nagato; Shinichiro Motohashi; Fumihiro Ishibashi; Kohsuke Okita; Kazuki Yamasaki; Yasumitsu Moriya; Hidehisa Hoshino; Shigetoshi Yoshida; Hideki Hanaoka; Shin-Ichiro Fujii; Masaru Taniguchi; Ichiro Yoshino; Toshinori Nakayama
Journal:  J Clin Immunol       Date:  2012-04-26       Impact factor: 8.317

Review 2.  Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.

Authors:  Wenji Sun; Priyanka B Subrahmanyam; James E East; Tonya J Webb
Journal:  J Interferon Cytokine Res       Date:  2012-10-10       Impact factor: 2.607

Review 3.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

4.  Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells.

Authors:  Toshiko Kamata; Akane Suzuki; Naoko Mise; Fumie Ihara; Mariko Takami; Yuji Makita; Atsushi Horinaka; Kazuaki Harada; Naoki Kunii; Shigetoshi Yoshida; Ichiro Yoshino; Toshinori Nakayama; Shinichiro Motohashi
Journal:  Cancer Immunol Immunother       Date:  2016-09-15       Impact factor: 6.968

Review 5.  Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy.

Authors:  Masaru Taniguchi; Michishige Harada; Nyambayar Dashtsoodol; Satoshi Kojo
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2015       Impact factor: 3.493

6.  Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine.

Authors:  Bo Li; Michael Siuta; Vanessa Bright; Dmitry Koktysh; Brittany K Matlock; Megan E Dumas; Meiying Zhu; Alex Holt; Donald Stec; Shenglou Deng; Paul B Savage; Sebastian Joyce; Wellington Pham
Journal:  Int J Nanomedicine       Date:  2016-11-16

Review 7.  NKT cells as an ideal anti-tumor immunotherapeutic.

Authors:  Shin-Ichiro Fujii; Kanako Shimizu; Yoshitaka Okamoto; Naoki Kunii; Toshinori Nakayama; Shinichiro Motohashi; Masaru Taniguchi
Journal:  Front Immunol       Date:  2013-12-02       Impact factor: 7.561

8.  Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells.

Authors:  Naoko Mise; Mariko Takami; Akane Suzuki; Toshiko Kamata; Kazuaki Harada; Tomoro Hishiki; Takeshi Saito; Keita Terui; Tetsuya Mitsunaga; Mitsuyuki Nakata; Takayuki Ikeuchi; Toshinori Nakayama; Hideo Yoshida; Shinichiro Motohashi
Journal:  Cancer Sci       Date:  2016-02-09       Impact factor: 6.716

Review 9.  Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.

Authors:  Mariko Takami; Fumie Ihara; Shinichiro Motohashi
Journal:  Front Immunol       Date:  2018-09-07       Impact factor: 7.561

Review 10.  The Role of NKT Cells in Glioblastoma.

Authors:  Emily E S Brettschneider; Masaki Terabe
Journal:  Cells       Date:  2021-06-30       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.